Can the breast screening appointment be used to provide risk assessment and prevention advice?

Breast Cancer Research

Table 1 Key NICE guideline recommendations relating to risk-based early detection and prevention strategies

Early detection and prevention strategies	Moderate risk Lifetime risk 17 % to 29 %	High risk Lifetime risk 30 % + 10-year risk 8 %+	Gene carriers and 30-50 % likelihood for TP53, BRCA1, or BRCA2
Early detection and prevention strategies	10-year risk 3 % to 7.9 % from age 40 to 49 years	High risk Lifetime risk 30 % + 10-year risk 8 %+
Mammography	Annual from age 40 to 49	Annual from age 40 to 59	Annual from age 40 to 69 except TP53
Magnetic resonance imaging	N/A	N/A	Annual from age 30 to 49, 25 to 59 for TP53
Tamoxifen	Consider 5 years of 20 mg daily	Offer 5 years of 20 mg daily	Offer 5 years of 20 mg daily
Raloxifene (post-menopausal)	Consider 5 years of 60 mg daily	Offer 5 years of 60 mg daily	Offer 5 years of 60 mg daily

ISSN: 1465-542X